Preclinical studies of a liposomal formulation of cisplatin have shown promising effects against ovarian, pancreatic, head and neck cancer, non-small cell lung cancer (NSCLC), and HER-2/neu–negative metastatic breast cancer [53,65,66,67,68]. This evidence concerns the gene ERBB2 and head and neck cancer.